Anti-Obesity Drugs Market Report and Forecast 2025-2034
Description
The anti-obesity drugs market was valued at USD 3.20 Billion in 2024, driven by rising prevalence of obesity across the 8 major markets. The market is expected to grow at a CAGR of 43.72% during the forecast period of 2025-2034, with the values likely to reach USD 120.32 Billion by 2034.
Anti-Obesity Drugs Market Overview
Anti-obesity drugs target different aspects of weight management such as appetite suppression, fat absorption, and metabolic enhancement. There are several anti-obesity drugs approved by the United States Food and Drug Administration (FDA) for long-term use, including Bupropion-naltrexone (Contrave), Liraglutide (Saxenda), Orlistat (Xenical, Alli), Phentermine-topiramate (Qsymia), and Semaglutide (Wegovy), among others. Some weight loss medications like semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound) can help in reducing body weight by 20%.
The anti-obesity drugs market growth is driven by the rising prevalence of obesity worldwide, increasing awareness about the health risks associated with obesity, and growing partnerships in obesity-related research. For instance, in February 2024, Obesity Canada partnered with My Viva Inc., in order to support people living with obesity. “My Viva Plan” created by My Viva is the lifestyle management tool useful for creating personalized fitness planning. Moreover, to raise the awareness among the individuals, International Obesity Collaborative (IOC), a global initiative aimed at addressing the obesity on international scale was also formed. The IOC comprised of 12 international organizations including the obesity medicine association. Furthermore, the surge in drug approvals by health regulatory agencies and innovation in drug development are some of the factors that are expected to positively influence the market landscape.
Anti-Obesity Drugs Market Growth Drivers
Rising Prevalence of Obesity to Foster the Market Landscape Significantly
The market is driven by rising prevalence of obesity which makes an individual prone to various health complications such as diabetes, cardiovascular diseases, and certain cancers. According to the World Health Organization (WHO), in 2022, around 2.5 billion adults (18 years or older) were overweight, out of which around 890 million adults were living with obesity. This equates to about 43% of the adults being overweight which shows an increase from the 1990, when 25% of adults aged 18 years and above were overweight. In addition, as per the latest World Obesity Atlas 2023, it is expected that the number of individuals falling in the overweight and obesity category will reach 4 billion by 2035. This indicates that every 1 in 5 women and 1 in 7 men, will be living with obesity by 2030.
Increased Strategic Merger and Initiatives to Meet Rising Anti-Obesity Drugs Market Demand
One of the significant market trends is the rise in strategic merger and acquisition initiatives taken by the key market players to expand production capacities and support the development of novel drug pipelines. Recently, in January 2024, Roche completed the acquisition of Carmot Therapeutics Inc. dedicated in developing the therapeutics for the people living with metabolic diseases including obesity and diabetes. Further, rising investments aimed at introducing safer and more efficient anti-obesity drugs in the market are also anticipated to accelerate market growth. In January 2024, Adipo Therapeutics closed a USD 1.9 million seed financing gap to advance the treatment of Type 2 diabetes and obesity.
Anti-Obesity Drugs Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Increased Focus on Combination Therapies
There is a growing interest in combination therapies that target multiple pathways to induce weight loss. Such combinations can offer better efficacy as compared to conventional monotherapies.
Heightened Patient Awareness
There is an increased awareness and acceptance of obesity as a chronic disease requiring medical intervention, rather than just lifestyle changes. This shift is contributing to the rising anti-obesity drugs market demand.
Regulatory Support
Regulatory agencies are providing transparent guidelines and support for the development and approval of anti-obesity drugs. This includes fast-track designations and approvals for drugs that exhibit significant benefits in clinical trials.
Increased Use of GLP-1 Receptor Agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for diabetes treatment, are increasingly preferred for obesity management due to their ability to induce weight loss.
Anti-Obesity Drugs Market Segmentation
"Global Anti-Obesity Drugs Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Breakup by Drug Type
Market Segmentation Based on Product Type is Anticipated to Witness Substantial Growth
By drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, and Tirzepatide. Each anti-obesity drug works on distinct mechanisms and shows different effects on weight management. Among the different anti-obesity drugs, the two anti-obesity drugs that have been approved for long-term usage are sibutramine and orlistat. However, they can even cause minor side-effects such as flatulence and diarrhea.
Anti-Obesity Drugs Market Analysis by Region
Based on region, United States is the market is witnessing significant growth which can attributed to an advanced healthcare system offering access to various anti-obesity drugs to the huge patient population. With 78% of adults in the United States estimated to be overweight or obese by 2030, the rising prevalence of obesity in the region is poised to propel the market growth in the coming years. In addition, the increased funding, and investments to support the development of novel weight loss drugs is expected to augment the anti-obesity drugs market demand.
Europe also holds a high market value, owing to the presence of leading market players in the region. Moreover, the dominance of the regional market is a result of the rising adoption of obesity treatment solutions and growing investments in obesity research and drug development. India is projected to witness substantial growth. It can be accredited to changing lifestyle of the people that can result in obesity.
Leading Players in the Anti-Obesity Drugs Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Novo Nordisk A/S
Established over 100 years ago, Novo Nordisk is a Danish pharmaceutical company that boasts a well-established anti-obesity drugs portfolio, including Wegovy and amycretin. Wegovy is a prescription based injectable while amycretin is an oral pill that works by stimulating gut hormones and controls blood sugar levels along with appetite.
Eli Lilly and Company
United States based Eli Lilly and Company spans across 18 countries. It has 2 major anti-obesity drugs including Mounjaro and Zepbound. Zepbound™ (tirzepatide) intended for chronic weight management received FDA approval in November 2023. The company has also initiated phase three clinical trials for a novel oral weight-loss drug called orforglipron in India.
Other major market players include Rhythm Pharmaceuticals, KVK Tech Inc., Currax Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Vivus LLC, Gelesis Holding Inc., GlaxoSmithKline PLC, Pfizer Inc., and Boehringer Ingelheim International GmbH.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in the Anti-Obesity Drugs Market Report
Anti-Obesity Drugs Market Overview
Anti-obesity drugs target different aspects of weight management such as appetite suppression, fat absorption, and metabolic enhancement. There are several anti-obesity drugs approved by the United States Food and Drug Administration (FDA) for long-term use, including Bupropion-naltrexone (Contrave), Liraglutide (Saxenda), Orlistat (Xenical, Alli), Phentermine-topiramate (Qsymia), and Semaglutide (Wegovy), among others. Some weight loss medications like semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound) can help in reducing body weight by 20%.
The anti-obesity drugs market growth is driven by the rising prevalence of obesity worldwide, increasing awareness about the health risks associated with obesity, and growing partnerships in obesity-related research. For instance, in February 2024, Obesity Canada partnered with My Viva Inc., in order to support people living with obesity. “My Viva Plan” created by My Viva is the lifestyle management tool useful for creating personalized fitness planning. Moreover, to raise the awareness among the individuals, International Obesity Collaborative (IOC), a global initiative aimed at addressing the obesity on international scale was also formed. The IOC comprised of 12 international organizations including the obesity medicine association. Furthermore, the surge in drug approvals by health regulatory agencies and innovation in drug development are some of the factors that are expected to positively influence the market landscape.
Anti-Obesity Drugs Market Growth Drivers
Rising Prevalence of Obesity to Foster the Market Landscape Significantly
The market is driven by rising prevalence of obesity which makes an individual prone to various health complications such as diabetes, cardiovascular diseases, and certain cancers. According to the World Health Organization (WHO), in 2022, around 2.5 billion adults (18 years or older) were overweight, out of which around 890 million adults were living with obesity. This equates to about 43% of the adults being overweight which shows an increase from the 1990, when 25% of adults aged 18 years and above were overweight. In addition, as per the latest World Obesity Atlas 2023, it is expected that the number of individuals falling in the overweight and obesity category will reach 4 billion by 2035. This indicates that every 1 in 5 women and 1 in 7 men, will be living with obesity by 2030.
Increased Strategic Merger and Initiatives to Meet Rising Anti-Obesity Drugs Market Demand
One of the significant market trends is the rise in strategic merger and acquisition initiatives taken by the key market players to expand production capacities and support the development of novel drug pipelines. Recently, in January 2024, Roche completed the acquisition of Carmot Therapeutics Inc. dedicated in developing the therapeutics for the people living with metabolic diseases including obesity and diabetes. Further, rising investments aimed at introducing safer and more efficient anti-obesity drugs in the market are also anticipated to accelerate market growth. In January 2024, Adipo Therapeutics closed a USD 1.9 million seed financing gap to advance the treatment of Type 2 diabetes and obesity.
Anti-Obesity Drugs Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Increased Focus on Combination Therapies
There is a growing interest in combination therapies that target multiple pathways to induce weight loss. Such combinations can offer better efficacy as compared to conventional monotherapies.
Heightened Patient Awareness
There is an increased awareness and acceptance of obesity as a chronic disease requiring medical intervention, rather than just lifestyle changes. This shift is contributing to the rising anti-obesity drugs market demand.
Regulatory Support
Regulatory agencies are providing transparent guidelines and support for the development and approval of anti-obesity drugs. This includes fast-track designations and approvals for drugs that exhibit significant benefits in clinical trials.
Increased Use of GLP-1 Receptor Agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for diabetes treatment, are increasingly preferred for obesity management due to their ability to induce weight loss.
Anti-Obesity Drugs Market Segmentation
"Global Anti-Obesity Drugs Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Breakup by Drug Type
- Semaglutide
- Phentermine/Topiramate
- Naltrexone/Bupropion
- Liraglutide
- Gelesis 100
- Orlistat
- Phentermine
- Methamphetamine
- Tirzepatide
- Others
- Amphetamine
- GLP-1 Receptor Agonist
- Lipase Inhibitor
- Others
- Centrally Acting Drugs
- Peripherally Acting Drugs
- Prescription Drugs
- Over The Counter Drugs
- Hospital Pharmacies
- Drug Store & Retail Pharmacies
- Online Pharmacies
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Product Type is Anticipated to Witness Substantial Growth
By drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, and Tirzepatide. Each anti-obesity drug works on distinct mechanisms and shows different effects on weight management. Among the different anti-obesity drugs, the two anti-obesity drugs that have been approved for long-term usage are sibutramine and orlistat. However, they can even cause minor side-effects such as flatulence and diarrhea.
Anti-Obesity Drugs Market Analysis by Region
Based on region, United States is the market is witnessing significant growth which can attributed to an advanced healthcare system offering access to various anti-obesity drugs to the huge patient population. With 78% of adults in the United States estimated to be overweight or obese by 2030, the rising prevalence of obesity in the region is poised to propel the market growth in the coming years. In addition, the increased funding, and investments to support the development of novel weight loss drugs is expected to augment the anti-obesity drugs market demand.
Europe also holds a high market value, owing to the presence of leading market players in the region. Moreover, the dominance of the regional market is a result of the rising adoption of obesity treatment solutions and growing investments in obesity research and drug development. India is projected to witness substantial growth. It can be accredited to changing lifestyle of the people that can result in obesity.
Leading Players in the Anti-Obesity Drugs Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Novo Nordisk A/S
Established over 100 years ago, Novo Nordisk is a Danish pharmaceutical company that boasts a well-established anti-obesity drugs portfolio, including Wegovy and amycretin. Wegovy is a prescription based injectable while amycretin is an oral pill that works by stimulating gut hormones and controls blood sugar levels along with appetite.
Eli Lilly and Company
United States based Eli Lilly and Company spans across 18 countries. It has 2 major anti-obesity drugs including Mounjaro and Zepbound. Zepbound™ (tirzepatide) intended for chronic weight management received FDA approval in November 2023. The company has also initiated phase three clinical trials for a novel oral weight-loss drug called orforglipron in India.
Other major market players include Rhythm Pharmaceuticals, KVK Tech Inc., Currax Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Vivus LLC, Gelesis Holding Inc., GlaxoSmithKline PLC, Pfizer Inc., and Boehringer Ingelheim International GmbH.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in the Anti-Obesity Drugs Market Report
- What was the anti-obesity drugs market value in 2023?
- What is the anti-obesity drugs market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on drug type?
- Who are the major distribution channels in the market?
- What are the major factors aiding the anti-obesity drugs market demand?
- How has the anti-obesity drugs market performed so far and how is it anticipated to perform in the coming years?
- What are the major trends influencing the market?
- What is the market breakup based on drug class?
- What is the market segmentation prescription type?
- What are the market's major drivers, opportunities, and restraints?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence of obesity affect the market landscape?
- Which drug type will dominate the market share?
- How does the changing lifestyle of the people will impact the market size?
- Which distribution channel will experience the highest demand in the market segment?
- Based on the mechanism of action, which segment will dominate the market?
- Which prescription type will dominate the market?
- Who are the key players involved in the anti-obesity drugs market?
- What is patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Anti-Obesity Drugs Market Overview – 8 Major Markets
- 3.1 Anti-Obesity Drugs Market Historical Value (2018-2024)
- 3.2 Anti-Obesity Drugs Market Forecast Value (2025-2034)
- 4 Obesity Overview
- 4.1 Guidelines and Stages
- 4.2 Pathophysiology
- 4.3 Screening and Diagnosis
- 4.4 Treatment Pathway
- 5 Patient Profile
- 5.1 Patient Profile Overview
- 5.2 Patient Psychology and Emotional Impact Factors
- 5.3 Risk Assessment and Treatment Success Rate
- 6 Anti-Obesity Drugs Epidemiology Scenario and Forecast – 8 Major Markets
- 6.1 8MM Epidemiology Scenario Overview (2018-2034)
- 6.2 United States Obesity Epidemiology Scenario and Forecast (2018-2034)
- 6.3 EU-4 and United Kingdom Obesity Epidemiology Scenario and Forecast (2018-2034)
- 6.3.1 Germany Obesity Epidemiology Scenario and Forecast (2018-2034)
- 6.3.2 France Obesity Epidemiology Scenario and Forecast (2018-2034)
- 6.3.3 Italy Obesity Epidemiology Scenario and Forecast (2018-2034)
- 6.3.4 Spain Obesity Epidemiology Scenario and Forecast (2018-2034)
- 6.3.5 United Kingdom Obesity Epidemiology Scenario and Forecast (2018-2034)
- 6.4 Japan Obesity Epidemiology Scenario and Forecast (2018-2034)
- 6.5 India Obesity Epidemiology Scenario and Forecast (2018-2034)
- 7 Anti-Obesity Drugs Market Landscape – 8 Major Markets
- 7.1 Anti-Obesity Drugs: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Anti-Obesity Drugs: Product Landscape
- 7.2.1 Analysis by Prescription Type
- 7.2.2 Analysis by Drug Type
- 7.2.3 Analysis by Drug Class
- 7.2.4 Analysis by Mechanism of Action
- 7.2.5 Analysis by Route of Administration
- 8 Anti-Obesity Drugs Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Anti-Obesity Drugs Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Anti-Obesity Drugs Market Segmentation (218-2034) - 8 Major Markets
- 11.1 Anti-Obesity Drugs Market (2018-2034) by Drug Type
- 11.1.1 Market Overview
- 11.1.2 Semaglutide
- 11.1.3 Phentermine/Topiramate
- 11.1.4 Naltrexone/Bupropion
- 11.1.5 Liraglutide
- 11.1.6 Gelesis 100
- 11.1.7 Orlistat
- 11.1.8 Phentermine
- 11.1.9 Methamphetamine
- 11.1.10 Tirzepatide
- 11.1.11 Others
- 11.2 Anti-Obesity Drugs Market (2018-2034) by Drug Class
- 11.2.1 Market Overview
- 11.2.2 Amphetamine
- 11.2.3 GLP-1 Receptor Agonist
- 11.2.4 Lipase Inhibitor
- 11.2.5 Others
- 11.3 Anti-Obesity Drugs Market (2018-2034) by Mechanism of Action
- 11.3.1 Market Overview
- 11.3.2 Centrally Acting Drugs
- 11.3.3 Peripherally Acting Drugs
- 11.4 Anti-Obesity Drugs Market (2018-2034) by Prescription Type
- 11.4.1 Market Overview
- 11.4.2 Prescription Drugs
- 11.4.3 Over The Counter Drugs
- 11.5 Anti-Obesity Drugs Market (2018-2034) by Distribution Channel
- 11.5.1 Market Overview
- 11.5.2 Hospital Pharmacies
- 11.5.3 Drug Store & Retail Pharmacies
- 11.5.4 Online Pharmacies
- 11.6 Anti-Obesity Drugs Market (2018-2034) by Region
- 11.6.1 Market Overview
- 11.6.2 United States
- 11.6.3 EU-4 and the United Kingdom
- 11.6.3.1 Germany
- 11.6.3.2 France
- 11.6.3.3 Italy
- 11.6.3.4 Spain
- 11.6.3.5 United Kingdom
- 11.6.4 Japan
- 11.6.5 India
- 12 United States Anti-Obesity Drugs Market (218-2034)
- 12.1 United States Anti-Obesity Drugs Market Historical Value (2018-2024)
- 12.2 United States Anti-Obesity Drugs Market Forecast Value (2025-2034)
- 12.3 United States Anti-Obesity Drugs Market (2018-2034) by Drug Type
- 12.3.1 Market Overview
- 12.3.2 Semaglutide
- 12.3.3 Phentermine/topiramate
- 12.3.4 Naltrexone/bupropion
- 12.3.5 Liraglutide
- 12.3.6 Gelesis 100
- 12.3.7 Orlistat
- 12.3.8 Phentermine
- 12.3.9 Methamphetamine
- 12.3.10 Tirzepatide
- 12.4 United States Anti-Obesity Drugs Market (2018-2034) by Mechanism of Action
- 12.4.1 Market Overview
- 12.4.2 Centrally Acting Drugs
- 12.4.3 Peripherally Acting Drugs
- 13 EU-4 and United Kingdom Anti-Obesity Drugs Market (218-2034)
- 13.1 EU-4 and United Kingdom Anti-Obesity Drugs Market Historical Value (2018-2024)
- 13.2 EU-4 and United Kingdom Anti-Obesity Drugs Market Forecast Value (2025-2034)
- 13.3 EU-4 and United Kingdom Anti-Obesity Drugs Market Overview
- 13.4 EU-4 and United Kingdom Anti-Obesity Drugs Market (2018-2034) by Drug Type
- 13.4.1 Market Overview
- 13.4.2 Semaglutide
- 13.4.3 Phentermine/topiramate
- 13.4.4 Naltrexone/bupropion
- 13.4.5 Liraglutide
- 13.4.6 Gelesis 100
- 13.4.7 Orlistat
- 13.4.8 Phentermine
- 13.4.9 Methamphetamine
- 13.4.10 Tirzepatide
- 13.5 EU-4 and United Kingdom Anti-Obesity Drugs Market (2018-2034) by Mechanism of Action
- 13.5.1 Market Overview
- 13.5.2 Centrally Acting Drugs
- 13.5.3 Peripherally Acting Drugs
- 14 Japan Anti-Obesity Drugs Market
- 14.1 Japan Anti-Obesity Drugs Market Historical Value (2018-2024)
- 14.2 Japan Anti-Obesity Drugs Market Forecast Value (2025-2034)
- 14.3 Japan Anti-Obesity Drugs Market (2018-2034) by Drug Type
- 14.3.1 Market Overview
- 14.3.2 Semaglutide
- 14.3.3 Phentermine/topiramate
- 14.3.4 Naltrexone/bupropion
- 14.3.5 Liraglutide
- 14.3.6 Gelesis 100
- 14.3.7 Orlistat
- 14.3.8 Phentermine
- 14.3.9 Methamphetamine
- 14.3.10 Tirzepatide
- 14.4 Japan Anti-Obesity Drugs Market (2018-2034) by Mechanism of Action
- 14.4.1 Market Overview
- 14.4.2 Centrally Acting Drugs
- 14.4.3 Peripherally Acting Drugs
- 15 India Anti- Obesity Drugs Market
- 15.1 India Anti-Obesity Drugs Market (2018-2034) Historical Value (2018-2024)
- 15.2 India Anti-Obesity Drugs Market (2018-2034) Forecast Value (2025-2034)
- 15.3 India Anti-Obesity Drugs Market (2018-2034) by Drug Type
- 15.3.1 Market Overview
- 15.3.2 Semaglutide
- 15.3.3 Phentermine/topiramate
- 15.3.4 Naltrexone/bupropion
- 15.3.5 Liraglutide
- 15.3.6 Gelesis 100
- 15.3.7 Orlistat
- 15.3.8 Phentermine
- 15.3.9 Methamphetamine
- 15.3.10 Tirzepatide
- 15.4 India Anti-Obesity Drugs Market (2018-2034) by Mechanism of Action
- 15.4.1 Market Overview
- 15.4.2 Centrally Acting Drugs
- 15.4.3 Peripherally Acting Drugs
- 16 Regulatory Framework
- 16.1 Regulatory Overview
- 16.1.1 US FDA
- 16.1.2 EU EMA
- 16.1.3 Japan PMDA
- 16.1.4 Others
- 17 Patent Analysis
- 17.1 Analysis by Type of Patent
- 17.2 Analysis by Publication Year
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Patent Age
- 17.5 Analysis by CPC Analysis
- 17.6 Analysis by Patent Valuation
- 17.7 Analysis by Key Players
- 18 Grants Analysis
- 18.1 Analysis by Year
- 18.2 Analysis by Amount Awarded
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Grant Application
- 18.5 Analysis by Funding Institute
- 18.6 Analysis by NIH Departments
- 18.7 Analysis by Recipient Organization
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Funding and Investment Analysis
- 20.1 Analysis by Funding Instances
- 20.2 Analysis by Type of Funding
- 20.3 Analysis by Funding Amount
- 20.4 Analysis by Leading Players
- 20.5 Analysis by Leading Investors
- 20.6 Analysis by Geography
- 21 Partnership and Collaborations Analysis
- 21.1 Analysis by Partnership Instances
- 21.2 Analysis by Type of Partnership
- 21.3 Analysis by Leading Players
- 21.4 Analysis by Geography
- 22 Supplier Landscape
- 22.1 GlaxoSmithKline PLC
- 22.1.1 Financial Analysis
- 22.1.2 Product Portfolio
- 22.1.3 Demographic Reach and Achievements
- 22.1.4 Mergers and Acquisitions
- 22.1.5 Certifications
- 22.2 Pfizer Inc.
- 22.2.1 Financial Analysis
- 22.2.2 Product Portfolio
- 22.2.3 Demographic Reach and Achievements
- 22.2.4 Mergers and Acquisitions
- 22.2.5 Certifications
- 22.3 Novo Nordisk A/S
- 22.3.1 Financial Analysis
- 22.3.2 Product Portfolio
- 22.3.3 Demographic Reach and Achievements
- 22.3.4 Mergers and Acquisitions
- 22.3.5 Certifications
- 22.4 Rhythm Pharmaceuticals
- 22.4.1 Financial Analysis
- 22.4.2 Product Portfolio
- 22.4.3 Demographic Reach and Achievements
- 22.4.4 Mergers and Acquisitions
- 22.4.5 Certifications
- 22.5 KVK Tech Inc.
- 22.5.1 Financial Analysis
- 22.5.2 Product Portfolio
- 22.5.3 Demographic Reach and Achievements
- 22.5.4 Mergers and Acquisitions
- 22.5.5 Certifications
- 22.6 Currax Pharmaceuticals LLC
- 22.6.1 Financial Analysis
- 22.6.2 Product Portfolio
- 22.6.3 Demographic Reach and Achievements
- 22.6.4 Mergers and Acquisitions
- 22.6.5 Certifications
- 22.7 CHEPLAPHARM Arzneimittel GmbH
- 22.7.1 Financial Analysis
- 22.7.2 Product Portfolio
- 22.7.3 Demographic Reach and Achievements
- 22.7.4 Mergers and Acquisitions
- 22.7.5 Certifications
- 22.8 Vivus LLC
- 22.8.1 Financial Analysis
- 22.8.2 Product Portfolio
- 22.8.3 Demographic Reach and Achievements
- 22.8.4 Mergers and Acquisitions
- 22.8.5 Certifications
- 22.9 Gelesis Holding Inc.
- 22.9.1 Financial Analysis
- 22.9.2 Product Portfolio
- 22.9.3 Demographic Reach and Achievements
- 22.9.4 Mergers and Acquisitions
- 22.9.5 Certifications
- 22.10 Boehringer Ingelheim International GmbH
- 22.10.1 Financial Analysis
- 22.10.2 Product Portfolio
- 22.10.3 Demographic Reach and Achievements
- 22.10.4 Mergers and Acquisitions
- 22.10.5 Certifications
- 22.11 Eli Lilly and Company
- 22.11.1 Financial Analysis
- 22.11.2 Product Portfolio
- 22.11.3 Demographic Reach and Achievements
- 22.11.4 Mergers and Acquisitions
- 22.11.5 Certifications
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
